Medtronic MDT Diabetes — Research and development expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Medtronic in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.
The official record: Medtronic’s 10-Q, filed February 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about Medtronic's diabetes — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Medtronic's diabetes — research and development expense?
- Medtronic (MDT) reported diabetes — research and development expense of $109M in Q4 2025.
- How has Medtronic's diabetes — research and development expense changed year-over-year?
- Medtronic's diabetes — research and development expense increased by 0.9% year-over-year, from $108M to $109M.
- What is the long-term trend for Medtronic's diabetes — research and development expense?
- Over 2 years (2023 to 2025), Medtronic's diabetes — research and development expense has grown at a 1.1% compound annual growth rate (CAGR), from $392M to $401M.
- What does diabetes — research and development expense mean?
- The amount spent on developing new diabetes products and improving existing technologies.
- How do you interpret diabetes — research and development expense?
- Higher spending indicates a focus on future growth and innovation, though it reduces short-term operating profit.
- How does diabetes — research and development expense compare across companies?
- Standard R&D expense metric used across all medical device and pharmaceutical companies.